Enzastaurin is an oral PKC-β inhibitor that is well-tolerated in newly diagnosed and relapsed/refractory DLBCL patients [200], and the second PCK inhibitor, sotrastaurin, is currently in clinical development for DLBCL [201]. The gene discussed is PRKCB; the disease is diffuse large B-cell lymphoma.